Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switching from Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF) vs maintaining TDF in chronic hepatitis B with genotypic resistance to adefovir or entecavir
KCT0003038Phase 4Completed
- Sponsor
- Gilead Sciences
- Start
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of tenofovir alafenamide in Chronic Hepatitis B (CHB), sponsored by Gilead Sciences. Started Oct 2017; status: completed.
02
Drugs
tenofovir alafenamide
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on KCT0003038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0003038.